Intensive antithrombotic therapy is necessary for long-term treatment in patients with symptomatic peripheral artery disease after acute myocardial infarction

Abstract Patients with acute myocardial infarction (AMI) who have concomitant peripheral artery disease (PAD) represent a subgroup at high risk of subsequent ischaemic events. This post hoc analysis of PRAGUE-18, a multicenter, randomised trial comparing prasugrel versus ticagrelor in primary PCI, a...

Повний опис

Бібліографічні деталі

Автори:	Jan Matejka, Zuzana Motovska, Ota Hlinomaz, Petr Kala, Milan Hromadka, Ivo Varvarovsky, Jaroslav Dusek, Jiri Jarkovsky, Richard Rokyta, Jan Mrozek, Pavel Cervinka, Stanislav Simek, Jiri Ostransky
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Nature Portfolio 2025-11-01
Серія:	Scientific Reports
Предмети:	Acute myocardial infarction Peripheral artery disease Antiplatelet therapy Ticagrelor Prasugrel
Онлайн доступ:	https://doi.org/10.1038/s41598-025-24372-2
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!